azurrx biopharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. ms1819 recombinant lipase for exocrine pancreatic insufficiency is the lead development program with additional early stage research being conducted for the prevention of hospital-acquired infection. the company is headquartered in new york, ny, with scientific operations based in langlade, france.
![Entero Therapeutics logo](/files/LOGO/1604191-placeholder.png)
Company profile
Ticker
ENTO
Exchange
Website
CEO
James Sapirstein
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
AzurRx BioPharma, Inc., BioPharma d'Azur, Inc., First Wave BioPharma, Inc.
SEC CIK
Corporate docs
Subsidiaries
First Wave Bio, Inc. • ImmunogenX, LLC ...
ENTO stock data
Latest filings (excl ownership)
S-3
Shelf registration
26 Jul 24
8-K
Departure of Directors or Certain Officers
23 Jul 24
8-K
Entero Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds
11 Jul 24
S-8
Registration of securities for employees
24 Jun 24
8-K
Departure of Directors or Certain Officers
20 Jun 24
PRER14A
Preliminary revised proxy
17 Jun 24
424B3
Prospectus supplement
14 Jun 24
EFFECT
Notice of effectiveness
11 Jun 24
8-K
Changes in Registrant's Certifying Accountant
5 Jun 24
S-3
Shelf registration
31 May 24
Transcripts
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.45 mm | 3.45 mm | 3.45 mm | 3.45 mm | 3.45 mm | 3.45 mm |
Cash burn (monthly) | 93.29 k | (no burn) | 3.10 mm | 1.75 mm | 1.25 mm | 1.11 mm |
Cash used (since last report) | 360.72 k | n/a | 11.98 mm | 6.77 mm | 4.83 mm | 4.28 mm |
Cash remaining | 3.09 mm | n/a | -8.52 mm | -3.31 mm | -1.38 mm | -825.58 k |
Runway (months of cash) | 33.2 | n/a | -2.8 | -1.9 | -1.1 | -0.7 |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Jul 24 | Sapirstein James | Common Stock | Sell | Dispose S | No | No | 1.07 | 1,289 | 1.38 k | 35,816 |
2 Jul 24 | Romano Sarah | Common Stock | Sell | Dispose S | No | No | 1.07 | 621 | 664.47 | 18,490 |
11 Jun 24 | Khosla Chaitan PHD | Common Stock | Grant | Acquire A | No | No | 0 | 24,889 | 0.00 | 24,889 |
1 Apr 24 | Romano Sarah | Common Stock | Sell | Dispose S | No | No | 4.2294 | 75 | 317.21 | 19,111 |
1 Apr 24 | Sapirstein James | Common Stock | Sell | Dispose S | No | No | 4.2294 | 174 | 735.92 | 37,105 |
News
Entero Therapeutics Announces Exercise Of Warrants And Issuance Of New Warrants In A Private Placement For $1.9M Gross Proceeds
11 Jul 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Jun 24
12 Health Care Stocks Moving In Monday's After-Market Session
10 Jun 24
12 Health Care Stocks Moving In Monday's Pre-Market Session
10 Jun 24
First Wave BioPharma Changes Name to Entero Therapeutics, Company Advances Toward Phase 3 Clinical Trial With Lead Asset – Latiglutenase For The Treatment Of Celiac Disease
16 May 24
Press releases
Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention
22 May 24
Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference
20 May 24
First Wave BioPharma Changes Name to Entero Therapeutics
16 May 24
First Wave BioPharma, Inc. to raise approximately $1.1 million of Gross Proceeds Priced At-the-Market
10 May 24